Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | FGF1 | P05230 | 1/20 | 0.38 |
| ▸ | FGF2 | P09038 | 1/20 | 0.38 |
| ▸ | VEGFA | P15692 | 1/20 | 0.38 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.38 |
| ▸ | CD209 | Q9NNX6 | 2/20 | 0.38 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.37 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.37 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.37 |
| ▸ | SELE | P16581 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | GJA1 | P17302 | 1/20 | 0.36 |
| ▸ | GJB2 | P29033 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | IGF2R | P11717 | 1/20 | 0.36 |
| ▸ | TYR | P14679 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17867221 | 1.00 | MEN1 (0.39) | MEN1KMT2AFGF1FGF2VEGFA | |
| SCHEMBL31460959 | 1.00 | MEN1 (0.39) | MEN1KMT2AFGF1FGF2VEGFA | |
| SCHEMBL22498757 | 0.94 | MEN1 (0.40) | MEN1KMT2AFGF1FGF2VEGFA | |
| SCHEMBL22498755 | 0.94 | MEN1 (0.40) | MEN1KMT2AFGF1FGF2VEGFA | |
| SCHEMBL14936496 | 0.93 | LGALS8 (0.44) | MEN1KMT2ALGALS8LGALS3LGALS4 | |
| SCHEMBL15373700 | 0.93 | LGALS8 (0.44) | MEN1KMT2ALGALS8LGALS3LGALS4 | |
| SCHEMBL14936334 | 0.93 | LGALS8 (0.44) | MEN1KMT2ALGALS8LGALS3LGALS4 | |
| SCHEMBL12362685 | 0.93 | LGALS8 (0.44) | MEN1KMT2ALGALS8LGALS3LGALS4 | |
| SCHEMBL17223127 | 0.93 | LGALS8 (0.44) | MEN1KMT2ALGALS8LGALS3LGALS4 | |
| Cellohexose SCHEMBL14796364 | 0.93 | LGALS8 (0.44) | MEN1KMT2ALGALS8LGALS3LGALS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083764-A1 | BETA-1,3'-GALACTOSYLLACTOSE FOR THE TREATMENT OF GUT BARRIER FUNCTION DISEASES | N.V. NUTRICIA (NL) | 2026-03-26 | — | — | US | claimed |
| US-12508273-B2 | Beta-1,3′-galactosyllactose for the treatment of gut barrier function diseases | N.V. NUTRICIA (NL) | 2025-12-30 | — | — | US | claimed |
| US-20220218728-A1 | BETA-1,3'-GALACTOSYLLACTOSE FOR THE TREATMENT OF GUT BARRIER FUNCTION DISEASES | N.V. NUTRICIA (NL) | 2022-07-14 | — | — | US | claimed |
| EP-3969009-A1 | BETA-1,3'-GALACTOSYLLACTOSE FOR THE TREATMENT OF GUT BARRIER FUNCTION DISEASES | N.V. Nutricia (NL) | 2022-03-23 | — | — | EP | claimed |
| US-20260083764-A1 | BETA-1,3'-GALACTOSYLLACTOSE FOR THE TREATMENT OF GUT BARRIER FUNCTION DISEASES | N.V. NUTRICIA (NL) | 2026-03-26 | — | — | US | disclosed |
| US-12508273-B2 | Beta-1,3′-galactosyllactose for the treatment of gut barrier function diseases | N.V. NUTRICIA (NL) | 2025-12-30 | — | — | US | disclosed |
| US-12465575-B2 | Methods of treatment using cholestosome vesicles for incorporation of molecules into chylomicrons | THERASYN SENSORS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4558645-A1 | METHOD FOR NUCLEIC ACID DETECTION USING SIGNAL-MEDIATED AMPLIFICATION OF RNA TECHNOLOGY AND RNA APTAMERS | Moirai Biodesign, S.L. (ES) | 2025-05-28 | — | — | EP | disclosed |
| US-20250144154-A1 | ALLOGRAFT TOLERANCE WITHOUT THE NEED FOR SYSTEMIC IMMUNE SUPPRESSION | SINAI HEALTH SYSTEM (CA) | 2025-05-08 | — | — | US | disclosed |
| US-12178835-B2 | Allograft tolerance without the need for systemic immune suppression | SINAI HEALTH SYSTEM (CA) | 2024-12-31 | — | — | US | disclosed |
| US-20240398719-A1 | CHOLESTOSOME VESICLES FOR INCORPORATION OF MOLECULES INTO CHYLOMICRONS | THERASYN SENSORS INC (US) | 2024-12-05 | — | — | US | disclosed |
| US-20240277739-A1 | NUTRITONAL COMPOSITIONS FOR GUT BARRIER FUNCTION | N.V. NUTRICIA (NL) | 2024-08-22 | — | — | US | disclosed |
| US-20230277471-A1 | METHODS OF TREATMENT USING CHOLESTOSOME VESICLES FOR INCORPORATION OF MOLECULES INTO CHYLOMICRONS | THERASYN SENSORS INC (US) | 2023-09-07 | — | — | US | disclosed |
| US-11633364-B2 | Methods of treatment using cholestosome vesicles for incorporation of molecules into chylomicrons | THERASYN SENSORS, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220325289-A1 | TOOLS AND METHODS FOR USING CELL DIVISION LOCI TO CONTROL PROLIFERATION OF CELLS | SINAI HEALTH SYSTEM (CA) | 2022-10-13 | — | — | US | disclosed |
| US-20220218728-A1 | BETA-1,3'-GALACTOSYLLACTOSE FOR THE TREATMENT OF GUT BARRIER FUNCTION DISEASES | N.V. NUTRICIA (NL) | 2022-07-14 | — | — | US | disclosed |
| US-20220110985-A1 | NUTRITIONAL COMPOSITION COMPRISING 2'FUCOSYLLACTOSE AND 3'GALACTOSYLLACTOSE | N.V. NUTRICIA (NL) | 2022-04-14 | — | — | US | disclosed |
| US-20220079962-A1 | NUTRITIONAL COMPOSITION COMPRISING 2'FUCOSYLLACTOSE AND DIETARY BUTYRATE | N.V. NUTRICIA (NL) | 2022-03-17 | — | — | US | disclosed |
| US-20190309289-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2019-10-10 | — | — | US | disclosed |
| US-20160186168-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083764-A1 | BETA-1,3'-GALACTOSYLLACTOSE FOR THE TREATMENT OF GUT BARRIER FUNCTION DISEASES | FABP2, GMFG, LTA | MEN1 3923/4885KMT2A 4716/4885FGF1 279/4885 |
| US-12508273-B2 | Beta-1,3′-galactosyllactose for the treatment of gut barrier function diseases | GALR1, GALR2, GALR3 | MEN1 4640/4885KMT2A 4413/4885FGF1 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.